Considering the functional importance and potential implications of the cis-PD-L1/CD80 interaction in pathologies such as cancer and autoimmune diseases, several recent studies have evaluated the possible therapeutic benefit of disrupting this interaction to modulate the balance of inhibitory and coactivating signals provided to T cells. This evidence concerns the gene CD274 and cancer.